Trials / Terminated
TerminatedNCT00526838
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous infusion in subjects with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL228 | 1-hour IV infusion |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2007-09-10
- Last updated
- 2015-08-21
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00526838. Inclusion in this directory is not an endorsement.